抑制剂简介
抑制剂是一类能够降低或阻止生物体内的酶活性、受体的活性或是细胞内特定反应过程的小分子化合物。它们在有机化学、化学化工和生物医药领域中有着广泛的应用,尤其是在药物研发方面。
分类与作用机制
应用领域
总结
抑制剂的研究和发展对于理解生命过程至关重要,并在药物开发、基础科学研究等多个领域发挥着重要作用。随着技术的进步,新的抑制剂不断被发现和开发出来,为医学治疗提供了更多的可能性。
中文名称 | 英文名称 | CAS号 | 化学式 | 结构式图片 |
---|---|---|---|---|
他克莫司 | Tacrolimus | 104987-11-3 | C44H69NO12 |
|
亮抑酶酞 | leupeptin | 24365-47-7 | C20H38N6O4 |
|
互变霉素 | tautomycin | 109946-35-2 | C41H66O13 |
|
二水合盐酸纳洛酮 | Naloxone hydrochloride dihydrate | 51481-60-8 | C19H26ClNO6 |
|
二(2-羟基-1-萘基)二硫醚 | bis-(2-hydroxy-1-naphthyl)disulphide | 42521-82-4 | C20H14O2S2 |
|
乙莫克舍 | (R)-(+)-etomoxir | 124083-20-1 | C17H23ClO4 |
|
乐铂 | Platinum,2R)-1,2-cyclobutanedimethanamine-kappaN,kappaN'][(2S)-2-(hydroxy-kappaO)propanoato(2-)-kappaO]-, (SP-4-3)-(9CI) (CA INDEX NAME) | 135558-11-1 | C9H16N2O3Pt |
|
乐伐替尼甲磺酸盐 | lenvatinib mesylate | 857890-39-2 | CH4O3S*C21H19ClN4O4 |
|
乐伐替尼 | lenvatinib | 417716-92-8 | C21H19ClN4O4 |
|
丹诺瑞韦 | Danoprevir | 850876-88-9 | C35H46FN5O9S |
|
丙亚胺 | razoxane | 21416-67-1 | C11H16N4O4 |
|
三氯苯哒唑 | triclabendazole | 68786-66-3 | C14H9Cl3N2OS |
|
三氟柳 | triflusal | 322-79-2 | C10H7F3O4 |
|
丁胺苯丙酮 | enzastaurin | 170364-57-5 | C32H29N5O2 |
|
丁布 | 2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one | 15893-52-4 | C9H9NO5 |
|
丁二酸洛沙平 | loxapine succinate | 27833-64-3 | C4H6O4*C18H18ClN3O |
|
丁二酸 4-氨基-5-氯-2,3-二氢-N-[1-(3-甲氧基丙基)-4-哌啶基]-7-苯并呋喃甲酰胺 | prucalopride succinate | 179474-85-2 | C4H6O4*C18H26ClN3O3 |
|
Γ-SECRETASE抑制剂(BMS-708163) | avagacestat | 1146699-66-2 | C20H17ClF4N4O4S |
|
mGlu5受体变构拮抗剂CTEP | CTEP | 871362-31-1 | C19H13ClF3N3O |
|
gsk 1292263; 5-[[[1-(3-异丙基-1,2,4-噁二唑-5-基)-4-哌啶基]甲基]氧基]-2-[4-(甲磺酰基)苯基]吡啶 | ((5-[({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}methyl)oxy]-2-[4-(methylsulfonyl)phenyl]pyridine)) | 1032823-75-8 | C23H28N4O4S |
|
alpha-苯基-N-[2,2,2-三氯-1-[[[(4-氟-3-硝基苯基)氨基]硫代甲酰]氨基]乙基]-苯乙酰胺 | CGK-733 | 905973-89-9 | C23H18Cl3FN4O3S |
|
alpha-环己基-5H-咪唑并[5,1-a]异吲哚-5-乙醇 | NLG919 | 1402836-58-1 | C18H22N2O |
|
[[(4-苯氧基苯基)磺酰基]甲基]噻丙环 | SB-3CT | 292605-14-2 | C15H14O3S2 |
|
[7-(6-氨基-3-吡啶基)-2,3-二氢-1,4-苯并氧氮杂卓-4(5H)-基][3-氟-2-甲基-4-(甲基磺酰基)苯基]-甲酮 | XL388 | 1251156-08-7 | C23H22FN3O4S |
|
[5-氟-2-甲基-3-(喹啉-2-基甲基)吲哚-1-基]乙酸 | (5-fluoro-2-methyl-3-quinolin-2-ylmethylindol-1-yl)acetic acid | 851723-84-7 | C21H17FN2O2 |
|
[5-[7-甲磺酰基-2-(吗啉-4-基)-6,7-二氢-5H-吡咯并[2,3-d]嘧啶-4-基]嘧啶-2-基]胺 | CH5132799 | 1007207-67-1 | C15H19N7O3S |
|
[5-[2,4-二((3S)-3-甲基吗啉-4-基)吡啶并[2,3-d]嘧啶-7-基]-2-甲氧基苯基]甲醇 | AZD8055 | 1009298-09-2 | C25H31N5O4 |
|
[4-氨基-2-[(1-甲磺酰基哌啶-4-基)氨基]嘧啶-5-基](2,3-二氟-6-甲氧基苯基)甲酮 | Ro 4584820 | 741713-40-6 | C18H21F2N5O4S |
|
[4-[[1-[(3-氟苯基)甲基]-1H-咪唑-5-基]氨基]-5-甲基吡咯[2,1-f][1,2,4]三嗪-6-基]-氨基甲酸-(3S)-3-吗啉甲酯 | [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid (3S)-3-morpholinylmethyl ester | 714971-09-2 | C27H27FN8O3 |
|
[4'-[3-甲基-4-[[[((R)-1-苯基乙基)氧基]羰基]氨基]异恶唑-5-基]联苯-4-基]乙酸 | AM095 | 1228690-36-5 | C27H24N2O5 |
|
[3-(4-吗啉基)苯基]硼酸盐酸盐 | VX 702 | 745833-23-2 | C19H12F4N4O2 |
|
[2-[1-[[3,5-双(三氟甲基)苯基]甲基]-5-(4-吡啶)-1H-1,2,3-噻唑-4-基]-3-吡啶](2-氯苯基)甲酮 | [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)-methanone | 622370-35-8 | C28H16ClF6N5O |
|
[1-[2-[5-(3-甲基氧杂环丁烷-3-基甲氧基)苯并咪唑-1-基]喹啉-8-基]哌啶-4-基]胺 | 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1H-benzo[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine | 670220-88-9 | C26H29N5O2 |
|
[1,3-二氢-5-[(4-甲基-1-哌嗪基)甲基]-2H-异吲哚-2-基][2,4-二羟基-5-(1-甲基乙基)苯基]甲酮 | AT13387 | 912999-49-6 | C24H31N3O3 |
|
[(1S,2S,5R)-2-异丙基-5-甲基环己基](二苯基)氧膦 | DPO-1 | 43077-30-1 | C22H29OP |
|
[(1S)-1-氰基-2-甲基丙基]氨基甲酸苄酯 | roscovitine | 186692-46-6 | C19H26N6O |
|
YK 4-279; 4,7-二氯-1,3-二氢-3-羟基-3-[2-(4-甲氧基苯基)-2-氧代乙基]-2H-吲哚-2-酮 | YK-4-279 | 1037184-44-3 | C17H13Cl2NO4 |
|
XL147类似物 | N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide | 956958-53-5 | C21H16N6O2S2 |
|
WZ 4002; N-[3-[[5-氯-2-[[2-甲氧基-4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氧基]苯基]-2-丙烯酰胺 | N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide | 1213269-23-8 | C25H27ClN6O3 |
|
WYE-687; N-[4-[4-(4-吗啉基)-1-[1-(3-吡啶甲基)-4-哌啶基]-1H-吡唑并[3,4-d]嘧啶-6-基]苯基]氨基甲酸甲酯 | WYE-687 | 1062161-90-3 | C28H32N8O3 |
|
WYE 354; 4-[6-[4-[(甲氧羰基)氨基]苯基]-4-(4-吗啉基)-1H-吡唑并[3,4-d]嘧啶-1-基]-1-哌啶羧酸甲酯 | WYE-354 | 1062169-56-5 | C24H29N7O5 |
|
WP 1066;(2E)-3-(6-溴-2-吡啶基)-2-氰基-N-[(1S)-1-苯基乙基]-2-丙烯酰胺 | WP 1066 | 857064-38-1 | C17H14BrN3O |
|
Verdinexor(KPT-335)抑制剂 | verdinexor | 1392136-43-4 | C18H12F6N6O |
|
VX-661/VX6611-(2,2-二氟-1,3-苯并二氧戊环-5-基)-N-[1-[(2R)-2,3-二羟基丙基]-6-氟-2-(2-羟基-1,1-二甲基乙基)-1H-吲哚-5-基]-环丙烷甲酰胺 | (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | 1152311-62-0 | C26H27F3N2O6 |
|
VU 0361737; N-(4-氯-3-甲氧基苯基)-2-吡啶甲酰胺 | VU0361737 | 1161205-04-4 | C13H11ClN2O2 |
|
V-9-M缩胆囊素九肽 | Valyl-prolyl-valyl-glutamyl-alanyl-valyl-aspartyl-prolyl-methionine | 99291-20-0 | C42H69N9O14S |
|
UK 383367; 5-[(1R)-4-环己基-1-[2-(羟基氨基)-2-氧代乙基]丁基]-1,2,4-恶二唑-3-甲酰胺 | UK-383367 | 348622-88-8 | C15H24N4O4 |
|
U0126;2,3-双[氨基[(2-氨基苯基)硫]亚甲基]丁二腈乙醇盐 | U0126-EtOH | 1173097-76-1 | C20H22N6OS2 |
|
TIE2激酶抑制剂 | Tie2 kinase inhibitor | 948557-43-5 | C26H21N3O2S |
|
TGF-ΒRECEPTORTYPEI/II抑制剂(LY2109761) | LY 2109761 | 700874-71-1 | C26H27N5O2 |
|